Montelukast Alvogen

Montelukast, the active ingredient in Montelukast Alvogen, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Alvogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene‑targeting medication used in several respiratory and allergic conditions. - Asthma (maintenance therapy): reduces the frequency of wheezing, shortness of breath and nighttime symptoms. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity, improving exercise tolerance.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Fatigue - Dizziness

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Mood changes including depression or suicidal thoughts - Hepatic enzyme elevations - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Eosinophilic pneumonia - Unexplained fever or systemic hypersensitivity

Before initiating therapy, consider the following safety points. - Pregnancy: consult a healthcare professional because safety data are limited. - Breastfeeding: weigh potential benefits against unknown risks to the infant. - Concomitant phenobarbital or strong CYP3A4 inducers: may reduce drug exposure, requiring monitoring. - Liver impairment: monitor hepatic function, especially in severe disease. - Elderly patients: use with caution due to possible increased sensitivity. - Store at ambient temperature: keep in the original container, protect from moisture and direct heat.

Montelukast can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may markedly decrease montelukast plasma concentrations. - Rifampin: can reduce therapeutic effect by inducing metabolism. - Strong CYP3A4 inducers (e.g., carbamazepine): may lower drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): monitor for mood changes or suicidal ideation. - ACE inhibitors: potential increased risk of angioedema. - Beta‑agonists: no direct pharmacokinetic interaction, but clinical response should be observed.